|
Medtronic Neuro Gets Warning Letter, FDA Wants to Meet on Motor Flaws
Medtronic’s neuromodulation unit has received an FDA warning letter on allegations the business segment did not handle complaints properly, among other corrective and preventive action (CAPA) violations.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives